Acute cholecystitis primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Administration of [[NSAIDs]] in the patients with [[biliary colic]] prevents the progression to acute cholecystitis. | Administration of [[NSAIDs]] in the patients with [[biliary colic]] prevents the progression to acute cholecystitis. | ||
==Primary Prevention== | ==Primary Prevention== | ||
*Administration of [[NSAIDs]] in the patients with [[biliary colic]] prevents the progression to acute cholecystitis.<ref name="pmid17252301">{{cite journal |vauthors=Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG |title=Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines |journal=J Hepatobiliary Pancreat Surg |volume=14 |issue=1 |pages=83–90 |year=2007 |pmid=17252301 |pmc=2784497 |doi=10.1007/s00534-006-1160-y |url=}}</ref><ref name="pmid9207282">{{cite journal |vauthors=Akriviadis EA, Hatzigavriel M, Kapnias D, Kirimlidis J, Markantas A, Garyfallos A |title=Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study |journal=Gastroenterology |volume=113 |issue=1 |pages=225–31 |year=1997 |pmid=9207282 |doi= |url=}}</ref> | *Administration of [[NSAIDs]] in the patients with [[biliary colic]] prevents the progression to acute cholecystitis.<ref name="pmid17252301">{{cite journal |vauthors=Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG |title=Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines |journal=J Hepatobiliary Pancreat Surg |volume=14 |issue=1 |pages=83–90 |year=2007 |pmid=17252301 |pmc=2784497 |doi=10.1007/s00534-006-1160-y |url=}}</ref><ref name="pmid9207282">{{cite journal |vauthors=Akriviadis EA, Hatzigavriel M, Kapnias D, Kirimlidis J, Markantas A, Garyfallos A |title=Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study |journal=Gastroenterology |volume=113 |issue=1 |pages=225–31 |year=1997 |pmid=9207282 |doi= |url=}}</ref> | ||
Revision as of 19:08, 18 December 2017
|
Acute cholecystitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute cholecystitis primary prevention On the Web |
|
American Roentgen Ray Society Images of Acute cholecystitis primary prevention |
|
Risk calculators and risk factors for Acute cholecystitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]
Overview
Administration of NSAIDs in the patients with biliary colic prevents the progression to acute cholecystitis.
Primary Prevention
- Administration of NSAIDs in the patients with biliary colic prevents the progression to acute cholecystitis.[1][2]
- NSAIDs such as diclofenac or indomethacin is used in the patients with biliary colic for their analgesic effects and their inhibition of prostaglandin release from the gallbladder wall.
- Administration of diclofenac (75 mg; intramuscular injection) in patients with biliary colic attack relieved the pain and prevented the progression of the disease to acute cholecystitis.[2]
References
- ↑ Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG (2007). "Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines". J Hepatobiliary Pancreat Surg. 14 (1): 83–90. doi:10.1007/s00534-006-1160-y. PMC 2784497. PMID 17252301.
- ↑ 2.0 2.1 Akriviadis EA, Hatzigavriel M, Kapnias D, Kirimlidis J, Markantas A, Garyfallos A (1997). "Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study". Gastroenterology. 113 (1): 225–31. PMID 9207282.